Try Web Version

Release Notes

Version 4.4.0

13 November 2025

November 2025

  1. Correction of syntax and spelling in several chapters.
  2. New page on kidney transplantation, by Drs. Gabriel Ouellet and Alexandra Viau-Trudel.
  3. Complete revision of the nephrology chapter.
  4. Update on pharmacologic management of heart failure with nonreduced ejection fraction according to the 2025 CCS guidelines.
  5. Revision of the Thyroid Cancer Page.
  6. Revision of the endocrinology chapter, in particular the section on thyroid nodules.
  7. Revision of the section on MGUS.
  8. Multiple minor corrections.


Version 4.3.5

19 September 2025


Minor corrections

Version 4.3.3

10 September 2025
  1. Correction of syntax and spelling.
  2. Merging of the Unstable Angina/Non–Q-wave Myocardial Infarction and ST-Elevation Myocardial Infarction pages into a new Acute Coronary Syndrome page.
  3. New summary section on prophylactic medications for malaria.
  4. New diagnostic classification of urinary tract infections (IDSA 2025).
  5. New section on trigeminal neuralgia in the Headache page.
  6. Modified protocol for alcohol withdrawal management.
  7. Update of the Lung Neoplasia page and addition of a web link to the PLCOm2012 equation.
  8. Update of the Fibromyalgia page with the most recent diagnostic criteria.
  9. Multiple minor corrections.


Version 4.3.1

30 June 2025


  1. Minor corrections to the acne table (translation errors).
  2. Multiples minor corrections.

Version 4.3.0

17 June 2025


  1. Update of the Arterial Hypertension table following the 2025 Hypertension Canada guidelines.
  2. Revisions to the Osteoporosis and Valvular Heart Disease tables.
  3. Addition of tirzepatide as a treatment option in the Obesity table.
  4. Addition of cenobamate to the Anticonvulsant table in the pharmacologic appendices.
  5. Multiple minor corrections.



Version 4.2.0

10 March 2025


  1. In-depth revision of the hematology chapter.
  2. Addition of a section on thalassemia.
  3. Correction of the CKD table (indications for reference in nephrology, addition of the KFRE score).
  4. New definition of obesity 2025.
  5. Addition of the EHMRG score in the heart failure table, decompensated heart failure section.
  6. Multiple minor corrections.



Version 4.1.3

12 February 2025


  1. Minor corrections.
  2. Modification to the table of contents.

Version 4.1.2

5 February 2025


Addition of the 2024 TNM table for lung cancer.


Addition of a section on the treatment of secondary hypertension.


Multiple minor corrections (eosinophilia, cirrhosis, tuberculosis…).


Version 4.1.1

21 January 2025
  1. Multiple minor corrections to various pages (Melanoma, Lung Cancer, Pulmonary Hypertension, Hypercalcemia, Hypertension, etc.).
  2. Corrections to certain figures (Stroke, Hyperkalemia).
  3. Update to the Drugs section (Appendix).

Version 4.1.0

26 August 2024
  1. Content updated with new guidelines
  2. Other minor adjustments

Version 4.0.7

9 April 2024
  • Significant revision of the respirology chapter.
  • Changes to the myasthenia gravis section (addition of the MGFA classification).
  • Addition of Lomitapide to the pharmacological appendix.

Version 4.0.6

9 December 2023
  • Update on Post-Myocardial Infarction Driving Guidelines (CCS 2023)
  • Inclusion of the EHRA Symptom Severity Scale in the atrial fibrillation section.
  • Minor modifications to several pages.
  • Addition of Omvoh in the pharmacological appendix.
  • Over 100 new references.

Version 4.0.5

6 November 2023
  • Update to the Osteoporosis page according to the new recommendations from Osteoporosis Canada 2023.


  • Multiple minor corrections in several chapters.


  • New medications in Appendix: abrocitinib, deucravacitinib, romosozumab.

Version 4.0.4

28 September 2023
  • Antiphospholipid Syndrome : added the ACR-EULAR 2023 diagnostic criteria
  • Minor edits
  • Bug fixes

Version 4.0.3

21 August 2023
  • Completed English translation for the newest edition.
  • Bugs and minor fixes.

Version 4.0.2

20 June 2023
  • New English edition (completed).
  • New references.
  • Integration of new criteria for infective endocarditis (Duke-ISCVID 2023).
  • Minor edits.

Version 4.0.0

22 May 2023
  • New edition completely updated after 8 months of work with many new co-authors and collaborators.
  • New pages: acne, myelodysplastic neoplasms.
  • New sections on preseptal cellulitis, orbital cellulitis, tick-borne viral encephalitis, and atrophic gastritis.
  • New drugs in the pharmacological appendix: finerenone, tirzepatide.
  • Over a hundred new references.
  • Technical fixes and improvements

Version 3.14.0

6 October 2022
  • New Chest X-Ray Abnormalities page.
  • New Monkeypox page.
  • Updated direct oral anticoagulants in the perioperative setting section (ACCP and ESC 2022).
  • Added ranolazine to the Drugs section (new sodium current inhibitor class)
  • Multiple minor edits to all chapters.
  • More than 50 new references


Version 3.13.1

4 August 2022
  • Updated recommendations for the prevention of contrast nephropathy in the ARF and CRF pages (according to CAR 2022)

Version 3.13.0

6 July 2022
  • New table on primary immunodeficiency, with the collaboration of Drs Hugues Allard-Chamard and Philippe Bilodeau.
  • Added a section on malignant catatonia to the Non-infectious Hyperthermia page.
  • Important corrections in gastroenterology and respirology.
  • Updated COVID-19 section.
  • Added Edmonton Obesity Staging System to obesity page.
  • Multiple minor fixes in all chapters.
  • More than 100 new references.

Version 3.12.0

17 May 2022
  • COVID update
  • Minor edits in all chapters.
  • New medication : Bimekizumab (Bimzelx)

Version 3.11.0

23 March 2022
  • Significant page edits: COVID-19, thyroid nodules, lung and thyroid cancer, etc.
  • Minor edits in all chapters.
  • New drugs: Adtralza (tralokinumab), Breztri Aerosphere (formoterol + budesonide + glycopyrronium), Effient (Prasugrel), Ilymia (tildrakizumab), Leqvio (inclisiran), Saphnelo (Anifrolumab).
  • Over 100 new references.

Version 3.10.1

6 September 2021
  • Revised General internal medicine and Neurology chapters.
  • Canadian Heart Failure and Dyslipidemia Guidelines updates integrated in the text.
  • Minor revisions to several chapters.
  • New drugs in the Drugs section (Appendix).
  • New collaborator: Prof. Michel Cauchon.
  • More than 100 new references.

Version 3.9.1

19 February 2021
  • New section: IgG4-Related Disease in General Internal Medicine chapter, made in collaboration with Drs Harold Bernatchez et Hugues Allard-Chamard.
  • Addition of tenecteplase in Thrombolysis in Stroke.
  • Addition of the Clinical Progression Scale in COVID-19 section.
  • Addition of the De Bakey classification in Aortic Dissection section.
  • Minor edits to all chapters.
  • New drugs in the Drugs section: Guselkumab (Tremfya), indacatérol + mometasone (Atectura breezhaler), indacaterol + glycopyrronium + mometasone (Enerzair breezhaler).
  • More than 100 new references.

Version 1.6.0

16 February 2021
  • COVID-19 section updates (treatment)
  • Modification to acetaminophen poisoning section
  • Minor edits to all chapters
  • More than 100 new references

Access trusted expertise in one place

Curated articles, case studies and updates from the author. Available on web, tablet and mobile. Flexible access for teams and institutions.

One subscription for all platforms